Common Pain Reliever Linked to Dramatic Reduction in Colorectal Cancer Recurrence
New York, NY – September 19, 2025 – A widely available over-the-counter medication, aspirin, has demonstrated a remarkable ability to halve the risk of colorectal cancer returning after initial treatment, according to findings presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The research, involving a comprehensive analysis of multiple clinical trials, offers a possibly simple and cost-effective strategy for improving outcomes for individuals diagnosed with this prevalent cancer.
Colorectal cancer remains a significant public health concern, projected to affect over 153,000 Americans in 2025 alone, according to the American Cancer Society. While advancements in treatment have improved survival rates, recurrence remains a major challenge. This new data suggests that regular aspirin use, under the guidance of a physician, could substantially alter the course of the disease for many patients following surgery or chemotherapy. The study’s implications are especially noteworthy given aspirin’s accessibility and low cost, potentially making preventative measures more equitable.
Researchers pooled data from eight randomized controlled trials encompassing over 2,000 patients who had undergone treatment for stage I-III colorectal cancer. The analysis revealed that those who consistently took aspirin – typically between 75mg and 325mg daily – for at least two years after completing primary treatment experienced a 47% reduction in the risk of cancer recurrence and a 32% decrease in overall mortality compared to those who did not.
“Thes findings are compelling and suggest that aspirin should be seriously considered as an adjuvant therapy for colorectal cancer patients,” stated Dr. Charles fuchs, Director of the Yale Cancer Center, and lead author of the study. “However, it’s crucial to emphasize that patients should not begin taking aspirin without first consulting their doctor, as it carries potential risks, including bleeding.”
The benefits appeared most pronounced in patients with tumors exhibiting high levels of microsatellite instability (MSI-H), a biomarker associated with a more favorable prognosis. Further research is underway to identify which patients are most likely to benefit from aspirin therapy and to determine the optimal dosage and duration of treatment. The study authors caution that long-term aspirin use can increase the risk of gastrointestinal bleeding and other side effects, necessitating careful evaluation and monitoring by a healthcare professional.
